caffeine has been researched along with levodopa in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (16.07) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 25 (44.64) | 29.6817 |
| 2010's | 18 (32.14) | 24.3611 |
| 2020's | 3 (5.36) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Giralt, E; Malakoutikhah, M; Teixidó, M | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Avdeef, A; Tam, KY | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Barber, S; Dew, TP; Farrell, TL; Poquet, L; Williamson, G | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Gaba, S; Gupta, GD; Monga, V; Patel, R; Saini, A; Singh, G | 1 |
| Hagino, K; Ikeda, M; Watanabe, H; Watanabe, K | 1 |
| Chase, T; Shoulson, I | 1 |
| Fujiwara, M; Oishi, R; Razzak, A; Ueki, S | 1 |
| Adams, JE; Harkins, D; Simpson, CC; White, BC | 1 |
| Cheng, LC; Rogus, EM; Zierler, K | 1 |
| Reus, VI | 1 |
| Hollister, LE | 1 |
| Chase, TN; Shoulson, I | 1 |
| Ikeda, M; Watanabe, H; Watanabe, K | 1 |
| Ichikawa, S; Kitamura, S; Kuwana, Y; Nakamura, J; Shiozaki, S; Yamada, K | 1 |
| Bonastre, M; Bové, J; Marin, C; Tolosa, E | 1 |
| Angelucci, ME; Canteras, NS; Da Cunha, C; Takahashi, RN; Wonnacott, S | 1 |
| Kim, DS; Palmiter, RD | 1 |
| Chen, JF | 1 |
| Dziubina, A; Gołembiowska, K | 3 |
| Chen, JF; Schwarzschild, MA; Yu, L | 1 |
| Cauli, O; Morelli, M; Pinna, A | 1 |
| Hnasko, TS; Palmiter, RD; Sotak, BN | 1 |
| Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J | 1 |
| Chand, P; Colwell, A; Deleu, D; Jacob, P; Sarre, S | 1 |
| Hnasko, TS; Palmiter, RD; Rainwater, AJ; Robinson, S | 1 |
| Barbanoj, M; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V | 1 |
| Kelsey, JE; Langelier, NA; Oriel, BS; Reedy, C | 1 |
| Barodia, SK; Luthra, PM; Raghubir, R | 1 |
| Ba, M; Kong, M; Liu, Z; Ma, Y; Song, L | 1 |
| Chen, JF; Herm, L; Kalda, A; Rinken, A; Zharkovsky, A | 1 |
| Burdett, TC; Cassin, JJ; Chen, JF; Fredholm, BB; Healy, B; Schwarzschild, MA; Xiao, D | 1 |
| Hu, WD; Huang, YX; Li, D; Liu, CF; Luo, WF | 1 |
| Darvas, M; Fadok, JP; Palmiter, RD | 1 |
| Chen, JF; Eberly, S; Kamp, C; Lang, AE; McDermott, MP; Messing, S; Oakes, D; Schwarzschild, MA; Tanner, CM; Tennis, M; Togasaki, D; Wills, AM | 1 |
| Jenner, P | 1 |
| Amboni, M; Barone, P; Erro, R; Longo, K; Moccia, M; Pellecchia, MT; Picillo, M; Vitale, C | 1 |
| Ahmed, H; Attia, D; Elfil, M; Essam, A; Farahat, E; Gabr, M; Negida, A | 1 |
| Sintov, AC | 1 |
| Bai, CH; Chan, L; Hong, CT | 1 |
| Manalo, RVM; Medina, PMB | 1 |
6 review(s) available for caffeine and levodopa
| Article | Year |
|---|---|
Adenosine receptor antagonists: Recent advances and therapeutic perspective.
Topics: Dose-Response Relationship, Drug; Humans; Molecular Structure; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Structure-Activity Relationship | 2022 |
Drugs and sexual behavior in man.
Topics: Amyl Nitrite; Barbiturates; Caffeine; Cannabis; Erectile Dysfunction; Ethanol; Gonadal Steroid Hormones; Humans; Levodopa; Lithium; Male; Nicotine; Opium; Sexual Behavior; Thioridazine | 1975 |
The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.
Topics: Animals; Caffeine; Disease Models, Animal; Humans; Levodopa; Memory Disorders; Neurons; Parkinsonian Disorders; Rats; Receptors, Dopamine; Receptors, Purinergic P1; Substantia Nigra | 2002 |
The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Brain; Caffeine; Dopamine; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Receptor, Adenosine A2A; Treatment Failure | 2003 |
Caffeine; the Forgotten Potential for Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Caffeine; Drug Synergism; Humans; Levodopa; Parkinson Disease | 2017 |
The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis.
Topics: Caffeine; Coffee; Cohort Studies; Disease Progression; Humans; Levodopa; Parkinson Disease; Proportional Hazards Models | 2020 |
3 trial(s) available for caffeine and levodopa
| Article | Year |
|---|---|
Caffeine and the antiparkinsonian response to levodopa or piribedil.
Topics: Adult; Aged; Caffeine; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil | 1975 |
Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 2006 |
Caffeine consumption and risk of dyskinesia in CALM-PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Benzothiazoles; Caffeine; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Retrospective Studies; Risk | 2013 |
47 other study(ies) available for caffeine and levodopa
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries.
Topics: Biological Transport; Blood-Brain Barrier; Cell Survival; Drug Carriers; Humans; Levodopa; Membranes, Artificial; Peptide Library; Peptides; Permeability; Phenylalanine; Solubility | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Cinnamates; Enterocytes; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Kinetics; Models, Biological; Molecular Conformation; Osmolar Concentration; Phenols | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Effects of dopaminergic stimulating agents, caffeine and antipsychotic drugs on rotational behaviour in mice with unilateral striatal 6-hydroxydopamine lesions (author's transl)].
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain Diseases; Caffeine; Corpus Striatum; Hydroxydopamines; In Vitro Techniques; Levodopa; Male; Methamphetamine; Methods; Mice; Receptors, Dopamine; Rotation | 1978 |
Possible involvement of a central noradrenergic system in automutilation induced by clonidine in mice.
Topics: 5-Hydroxytryptophan; Animals; Brain; Brain Chemistry; Caffeine; Catecholamines; Chlorpromazine; Clonidine; Dose-Response Relationship, Drug; Drug Synergism; Fenclonine; Humans; Levodopa; Male; Methamphetamine; Methyltyrosines; Mice; Phenoxybenzamine; Phentolamine; Reserpine; Self Mutilation; Sympathetic Nervous System; Theophylline | 1977 |
Monoamine synthesis and caffeine-induced locomotor activity.
Topics: Animals; Biogenic Amines; Caffeine; Fenclonine; Levodopa; Male; Methyltyrosines; Motor Activity; Rats; Time Factors | 1978 |
beta-Adrenergic effect on Na+-K+ transport in rat skeletal muscle.
Topics: Animals; Biological Transport, Active; Bucladesine; Caffeine; Catechols; Isoproterenol; Kinetics; Levodopa; Male; Models, Biological; Muscles; Ouabain; Oxidation-Reduction; Potassium; Rats; Sodium | 1977 |
Behavioral side effects of medical drugs.
Topics: Adrenal Cortex Hormones; Aged; Antihypertensive Agents; Antitubercular Agents; Aspirin; Behavior; Caffeine; Cimetidine; Contraceptives, Oral, Hormonal; Digitalis Glycosides; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Levodopa; Male; Mental Disorders; Parasympatholytics; Placebos; Propranolol; Psychoses, Substance-Induced; Reserpine; Sympathomimetics; Thyroid Hormones | 1979 |
Dopaminergic mechanisms in patients with extrapyramidal disease.
Topics: Animals; Biogenic Amines; Brain; Caffeine; Clonidine; Dopamine; Drug Evaluation; Drug Therapy, Combination; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Parasympatholytics; Parkinson Disease; Piperazines; Piribedil; Pituitary Gland, Anterior; Prolactin; Rats; Receptors, Drug; Stimulation, Chemical | 1975 |
Development of tolerance to dopaminergic stimulating effect of theophylline in mice with unilateral striatal 6-hydroxydopamine lesions.
Topics: Animals; Caffeine; Corpus Striatum; Drug Tolerance; Humans; Hydroxydopamines; Levodopa; Male; Mice; Receptors, Dopamine; Stereotyped Behavior; Theophylline | 1982 |
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Antiparkinson Agents; Antipsychotic Agents; Caffeine; Catalepsy; Dopamine Agents; Hypokinesia; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Phenethylamines; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Reserpine; Theophylline | 1999 |
Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
Topics: Animals; Caffeine; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1 | 2002 |
Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice.
Topics: Amygdala; Animals; Body Weight; Brain; Caffeine; Central Nervous System Stimulants; Cyclic AMP; Dopamine; Dose-Response Relationship, Drug; Genotype; Hypothalamus; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Proto-Oncogene Proteins c-fos; Receptors, Purinergic P1; Signal Transduction; Time Factors | 2003 |
Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Benserazide; Brain Chemistry; Caffeine; Corpus Striatum; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Microdialysis; Rats; Rats, Wistar; Reserpine | 2004 |
Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Caffeine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Time Factors | 2006 |
Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Caffeine; Central Nervous System Stimulants; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics | 2005 |
Morphine reward in dopamine-deficient mice.
Topics: Analgesics, Opioid; Animals; Brain; Caffeine; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Levodopa; Mice; Morphine; Motor Activity; Pain; Pain Threshold; Reward; Tail; Tyrosine 3-Monooxygenase | 2005 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger | 2006 |
Viral restoration of dopamine signaling to the dorsal striatum restores instrumental conditioning to dopamine-deficient mice.
Topics: Adenoviruses, Canine; Animals; Association Learning; Behavior, Animal; Caffeine; Central Nervous System Stimulants; Conditioning, Operant; Corpus Striatum; Cues; Dopamine; Dopamine Agents; Dopamine beta-Hydroxylase; Feeding Behavior; Gene Transfer Techniques; Genetic Vectors; Levodopa; Male; Mice; Mice, Knockout; Motivation; Motor Activity; Reinforcement Schedule; Reward; Substantia Nigra; Tyrosine 3-Monooxygenase | 2007 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Benzylamines; Brain; Caffeine; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2007 |
The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Globus Pallidus; Injections; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Long-Evans | 2009 |
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutathione; Haloperidol; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Posture; Superoxide Dismutase; Swimming | 2009 |
Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Dopamine and cAMP-Regulated Phosphoprotein 32; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Motor Activity; Movement; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Signal Transduction; Up-Regulation | 2009 |
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Benzazepines; Caffeine; Corpus Striatum; Dopamine Agonists; Drug Therapy, Combination; Guanosine 5'-O-(3-Thiotriphosphate); Levodopa; Lisuride; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulfur Radioisotopes | 2009 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinson Disease; Protein Precursors; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptor, Adenosine A2A; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2011 |
CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Blotting, Western; Brain; Caffeine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Transmission; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Synapses | 2011 |
Requirement of dopamine signaling in the amygdala and striatum for learning and maintenance of a conditioned avoidance response.
Topics: Amygdala; Analysis of Variance; Animals; Avoidance Learning; Caffeine; Caveolin 2; Central Nervous System Stimulants; Conditioning, Classical; Corpus Striatum; Dopamine; Dopamine Agents; Escape Reaction; Fear; Levodopa; Mice; Mice, Knockout; Reaction Time; Signal Transduction; Tyrosine 3-Monooxygenase | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Caffeine; Corpus Striatum; Dopamine; Dopamine Agents; Extracellular Space; Glutamic Acid; Homovanillic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Oxidative Stress; Rats; Rats, Wistar; Reserpine; Triazines; Triazoles; Vesicular Monoamine Transport Proteins | 2012 |
A cup of coffee a day keeps dyskinesia away?
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Benzothiazoles; Caffeine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Pramipexole | 2013 |
Caffeine consumption and the 4-year progression of de novo Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Caffeine; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Quality of Life; Surveys and Questionnaires; Time Factors | 2016 |
Cumulative evidence of the low reliability of frozen/thawed pig skin as a model for in vitro percutaneous permeation testing.
Topics: Administration, Cutaneous; Animals; Caffeine; Cryopreservation; Diclofenac; Freezing; In Vitro Techniques; Levodopa; Permeability; Reproducibility of Results; Skin; Skin Absorption; Swine | 2017 |
Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Caffeine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Levodopa; Locomotion; Neuroprotective Agents; Parkinsonian Disorders | 2020 |